06:00 PM EDT, 08/27/2024 (MT Newswires) -- Eagle Pharmaceuticals ( EGRX ) said Tuesday it has been notified by Nasdaq that its failure to timely file a Form 10-Q report for the quarter ended June 30 serves as an additional and separate basis for delisting.

The company said Nasdaq had previously granted its request for continued listing, subjecting to the filing on or before Sept. 30 of its 2023 annual report on Form 10-K, and the filing on or before Oct. 31 of a Form 10-Q report for the quarter ended March 31 and a Form 10-Q for Q2.

Eagle said it is working to prepare and file the delayed reports with the Securities and Exchange Commission by the applicable compliance dates to regain compliance with listing rules.

Price: 4.6600, Change: -0.10, Percent Change: -2.10